XML 23 R11.htm IDEA: XBRL DOCUMENT v3.23.1
RESTRUCTURING
 12 Months Ended
Apr. 01, 2023
Restructuring and Related Activities [Abstract]  
RESTRUCTURING RESTRUCTURING
On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.

In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During fiscal 2022, the Company revised the program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The Company expects to incur aggregate charges between $95 million and $105 million by the end of fiscal 2025 under the program. The majority of charges will result in cash outlays, including severance and other employee costs, and will be incurred as the specific actions required to execute these initiatives are identified and approved. During fiscal 2023, 2022 and 2021, the Company incurred $11.5 million, $28.7 million and $15.1 million of restructuring and restructuring related costs under this program, respectively. Total cumulative charges under this program are $67.2 million as of April 1, 2023.
The following table summarizes the activity for restructuring reserves related to the 2020 Program and prior programs for the fiscal years ended April 1, 2023, April 2, 2022 and April 3, 2021, substantially all of which relates to employee severance and other employee costs:
(In thousands)2020 ProgramPrior ProgramsTotal
Balance at March 28, 2020$1,136 $1,512 $2,648 
Costs incurred, net of reversals1,501 (57)1,444 
Payments(2,062)(1,018)(3,080)
Balance at April 3, 2021$575 $437 $1,012 
Costs incurred, net of reversals4,202 28 4,230 
Payments(2,317)(120)(2,437)
Balance at April 2, 2022$2,460 $345 $2,805 
Costs incurred, net of reversals576 81 657 
Payments(1,226)(86)(1,312)
Balance at April 1, 2023$1,810 $340 $2,150 

The following presents the restructuring costs by line item during fiscal 2023, 2022 and 2021 within our accompanying consolidated statements of income and comprehensive income:
(In thousands) 202320222021
Cost of goods sold$(215)$2,236 $390 
Research and development— 105 142 
Selling, general and administrative expenses872 1,889 912 
Total$657 $4,230 $1,444 

As of April 1, 2023, the Company had a restructuring liability of $2.2 million, of which approximately $1.8 million is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, the Company also incurred costs of $10.9 million, $24.6 million and $14.2 million in fiscal 2023, 2022 and 2021, respectively, that do not constitute restructuring costs under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions.

The following presents the restructuring related costs by line item during fiscal 2023, 2022 and 2021 within our accompanying consolidated statements of income and comprehensive income:
(In thousands) 202320222021
Cost of goods sold$7,991 $17,832 $9,318 
Research and development1,050 714 1,026 
Selling, general and administrative expenses1,851 6,048 3,873 
Total$10,892 $24,594 $14,217 
The tables below present restructuring and restructuring related costs by reportable segment:
Restructuring costs
(In thousands) 202320222021
Plasma$(48)$2,492 $454 
Blood Center— (18)201 
Hospital165 (93)322 
Corporate540 1,849 467 
Total$657 $4,230 $1,444 
Restructuring related costs
(In thousands) 202320222021
Plasma$1,385 $7,906 $1,870 
Blood Center75 556 1,599 
Hospital546 379 14 
Corporate8,886 15,753 10,734 
Total$10,892 $24,594 $14,217 
Total restructuring and restructuring related costs$11,549 $28,824 $15,661